CN109420175A - Mechanism of blood glucose regulation based on COX - Google Patents
Mechanism of blood glucose regulation based on COX Download PDFInfo
- Publication number
- CN109420175A CN109420175A CN201710781391.9A CN201710781391A CN109420175A CN 109420175 A CN109420175 A CN 109420175A CN 201710781391 A CN201710781391 A CN 201710781391A CN 109420175 A CN109420175 A CN 109420175A
- Authority
- CN
- China
- Prior art keywords
- ppar
- cox
- regulator
- drug
- gpr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 53
- 239000008103 glucose Substances 0.000 title claims abstract description 53
- 210000004369 blood Anatomy 0.000 title claims abstract description 43
- 239000008280 blood Substances 0.000 title claims abstract description 43
- 230000007246 mechanism Effects 0.000 title claims abstract description 15
- 230000033228 biological regulation Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 48
- 229940079593 drug Drugs 0.000 claims abstract description 40
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 39
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims abstract description 24
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims abstract description 24
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 18
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims abstract description 8
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 7
- 230000003914 insulin secretion Effects 0.000 claims abstract description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 34
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 28
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 claims description 21
- 229960005095 pioglitazone Drugs 0.000 claims description 17
- 108010016731 PPAR gamma Proteins 0.000 claims description 14
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims description 12
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims description 12
- 102000004877 Insulin Human genes 0.000 claims description 12
- 108090001061 Insulin Proteins 0.000 claims description 12
- 102000000536 PPAR gamma Human genes 0.000 claims description 12
- -1 Xi Gelieting Chemical compound 0.000 claims description 12
- 229940125396 insulin Drugs 0.000 claims description 12
- 108010015181 PPAR delta Proteins 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 102000023984 PPAR alpha Human genes 0.000 claims description 9
- 108010028924 PPAR alpha Proteins 0.000 claims description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 9
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 9
- 230000009102 absorption Effects 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 9
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 8
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 claims description 6
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 6
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 claims description 6
- 239000004744 fabric Substances 0.000 claims description 6
- 102100040136 Free fatty acid receptor 3 Human genes 0.000 claims description 5
- 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims description 5
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 claims description 5
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 claims description 5
- 101000890662 Homo sapiens Free fatty acid receptor 3 Proteins 0.000 claims description 5
- 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims description 5
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 claims description 5
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 claims description 4
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000004026 insulin derivative Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229960004586 rosiglitazone Drugs 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
- 108010019598 Liraglutide Proteins 0.000 claims description 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 3
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 3
- 229960002632 acarbose Drugs 0.000 claims description 3
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
- 229960004580 glibenclamide Drugs 0.000 claims description 3
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 229960002701 liraglutide Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940124638 COX inhibitor Drugs 0.000 claims description 2
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 2
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 229940124639 Selective inhibitor Drugs 0.000 claims description 2
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229960004733 albiglutide Drugs 0.000 claims description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 claims description 2
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960004277 benorilate Drugs 0.000 claims description 2
- 229960001713 canagliflozin Drugs 0.000 claims description 2
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229950009226 ciglitazone Drugs 0.000 claims description 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003834 dapagliflozin Drugs 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- 239000010248 fenbid Substances 0.000 claims description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001395 fenbufen Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 229960000346 gliclazide Drugs 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001381 glipizide Drugs 0.000 claims description 2
- 230000004153 glucose metabolism Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000008676 import Effects 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229950000991 ipragliflozin Drugs 0.000 claims description 2
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229950004397 luseogliflozin Drugs 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002702 piroxicam Drugs 0.000 claims description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 108700027806 rGLP-1 Proteins 0.000 claims description 2
- 230000030558 renal glucose absorption Effects 0.000 claims description 2
- 229960002354 repaglinide Drugs 0.000 claims description 2
- 229960004937 saxagliptin Drugs 0.000 claims description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 2
- 108010033693 saxagliptin Proteins 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229950006667 tofogliflozin Drugs 0.000 claims description 2
- 210000003462 vein Anatomy 0.000 claims description 2
- 229960001254 vildagliptin Drugs 0.000 claims description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 claims 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960003468 gliquidone Drugs 0.000 claims 1
- 229960001110 miglitol Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 17
- 238000011740 C57BL/6 mouse Methods 0.000 description 16
- 238000005259 measurement Methods 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- BZCALJIHZVNMGJ-HSZRJFAPSA-N Fasiglifam Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC=2C=C3OC[C@@H](CC(O)=O)C3=CC=2)=C1 BZCALJIHZVNMGJ-HSZRJFAPSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 238000007410 oral glucose tolerance test Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 6
- 239000000890 drug combination Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 229940123464 Thiazolidinedione Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 229940125827 GPR40 agonist Drugs 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101150050349 FFAR2 gene Proteins 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 101150108864 Ffar1 gene Proteins 0.000 description 1
- 101150008543 Ffar3 gene Proteins 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 101100264077 Xenopus laevis wrn gene Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to biomedicine fields, are related to the mechanism of blood glucose regulation of the multiple target point of COX participation.The present invention provides new prevention or the mechanism for the treatment of diabetes, metabolic syndrome and its related disease.Drug or pharmaceutical composition can protect beta Cell of islet, adjust insulin secretion or increase insulin sensitivity to adjust blood glucose by acting on COX and/or GPR and/or PPAR multiple target point.Thus, the present invention will be to prevent or treatment diabetes, metabolic syndrome and its related disease provide a kind of new way and means.
Description
Technical field
The invention belongs to biomedicine fields, are related to the mechanism of blood glucose regulation of the multiple target point of COX participation.The present invention provides pre-
Anti- or treatment diabetes, metabolic syndrome and its related disease mechanism, drug or pharmaceutical composition can be by acting on
COX and/or GPR and/or PPAR multiple target point protection beta Cell of islet adjust insulin secretion or increase insulin sensitivity to adjust
Save blood glucose.Thus, the present invention will provide a kind of new way to prevent or treating diabetes, metabolic syndrome and its related disease
And means.
Background technique
Diabetes are a kind of energetic supersession diseases, are broadly divided into type 1 diabetes (insulin-dependent diabetes mellitus) and 2 types sugar
Urinate sick (non-insulin-dependent diabetes mellitus).There are about 3.66 hundred million diabetics in the whole world at present, account for the 6.4% of world population,
Middle type 2 diabetic patient accounts for about the 90 ~ 95% of diabetic's sum.
Diabetes can pass through dietary adjustments and exercise treatment.When these cannot alleviate symptom, needs to carry out drug and control
It treats.The drug treatment of diabetes includes: biguanides at present, such as melbine, can reduce the formation of glucose in liver；
Sulfonylurea, such as glibenclamide, being capable of the more insulin of stimulating pancreas β cell secretion；Thiazolidinediones, as pyrrole lattice arrange
Ketone enhances the Purificatiou of insulin by activation peroxisome proliferator activated receptor γ (PPAR- γ)；Alpha-glucosaccharase
Enzyme inhibitor, such as acarbose are able to suppress the generation of glucose in enteron aisle；Glucagon-like-peptide-1 (GLP-1) analog,
Such as Liraglutide, the β cells secrete insulin of pancreas can be promoted；DPP IV (DPP-IV) inhibitor, such as Xi Gelie
Spit of fland is able to suppress the degradation of internal GLP-1.But the method for existing treatment diabetes has certain defect.Such as pancreas islet
Essence injecta and sulfonylurea may cause hypoglycemia and weight gain side effect；Melbine class, alpha-glucosidase inhibit
Agent and GLP-1 analog may cause gastrointestinal side effect；PPAR- gamma agonist may cause weight gain and oedema pair is made
With；DPP-IV inhibitor may cause epipharyngitis, headache and infection side effect.Research for multiple fields is carrying out,
To bring more effective novel blood sugar lowing drug for market.
Cyclooxygenase (cyclooxygenase, COX), also known as prostaglandin endoperoxides synzyme (PGHs), have
Two kinds of isodynamic enzymes of COX-1 and COX-2, be the key that prostaglandin synthesis rate-limiting enzyme, can conversion of arachidonic acid generate it is various before
Column parathyrine and thromboxane A2(TXA2), to generate various physiological and pathological effects.COX-1 is the structure for participating in normal physiological effect
Enzyme, the effects of participating in protection gastrointestinal tract mucosa, adjust renal hemodynamic and promote platelet aggregation；COX-2 is induced enzyme, in physiology shape
Under state, COX-2 can't detect in internal most of tissues, can then be promoted each with great expression under the induction of inflammatory factor
Kind prostaglandin synthesis, the reaction such as mediated pain, inflammation and fever.The inflammation that COX is mediated is that diabetic heart disease occurs
Breaking-out, apoplexy, a main cause of kidney problems and other related complications.
Free-fat acid acceptor (FFAR) is the g protein coupled receptor (GPRs) for going orphanization in recent years.It has determined that at present
Free-fat acid acceptor have G G-protein linked receptor 40(GPR40) family, including GPR40(is also referred to as free-fat acid acceptor 1,
FFA1), GPR41(also referred to as also referred to as free-fat acid acceptor 3, FFA3), GPR43(be also referred to as free-fat acid acceptor 2, FFA2) and
GPR84, GPR120 of other families.GPR40 is to find new galanin-galanin receptors (GALR) Asia
The orphan type GPCR found when type, is highly expressed in the cell line of pancreatic beta cell and excreting insulin.GPR40 can be in conjunction with such as
Palmitic acid, stearic acid, oleic acid, the free fatty acid in the blood plasma such as linoleic acid plus linolenic acid realize various physiological-function.Such as it is long
Chain free fatty acid in conjunction with GPR40 after activate GPR40, in inducing cell calcium ion level increase, enhancing glucose stimulation
The secretion (GSIS) of insulin.GPR40 regulator plays incretin and acts on to promote GSIS, furthermore can also be with a variety of treatments
Diabetes medicament is used in combination.Based on the above, GPR40 agonist can treat diabetes and related indication, especially 2 types sugar
Urine disease, obese insulin are resisted, poor glucose tolerance and other indications.With GPR40 for potential therapy target, hair
Now there is important researching value and application prospect with compound of the transformation with GPR40 agonist activity.
A series of patent application of GPR regulators is disclosed at present, including WO2004041266,
WO2005087710, WO2005051890, WO2006083781, WO2007013689, WO2008066097,
WO2009054390, WO2010085525, WO2011008663, WO2009038974, WO2011/140160 etc., the mono- target spot of GPR
The mechanism of blood glucose regulation of mediation has become the hot spot studied at present.
Agent for peroxisome proliferator activated receptor (peroxisome proliferators-activated
Receptors, PPARs) it is ligand activation receptor in nuclear hormone receptor families, its is had discovered that in different species
3 kinds of hypotypes control many intracellular metabolic processes, belong to ligand induced nuclear receptor.PPAR α liver, skeletal muscle, kidney,
It is highly expressed in heart and vascular wall, the expression quantity in fat and cartilage is relatively low.PPAR δ wide expression in vivo,
Brain, stomach, the expression of colon relative high levels.PPAR γ is mainly expressed in fat cell, it is to adjust Adipocyte Differentiation
Important transcription factor.PPAR γ can promote white Adipocyte Differentiation to reduce at numerous small fat cells after being activated
The quantity of big fat cell.Research shows that small fat cell has higher insulin sensitivity for maxicell,
So as to preferably utilize glucose.In addition, molecular biology experiment in recent years has determined that PPAR γ is insulin sensitivity enhancing
The target spot of agent Thiazolidinediones (thiazolidinediones, TZDs) effect.This kind of drug in conjunction with PPAR γ with
After can activate this receptor, to regulate and control a series of important physiology courses.On the one hand the PPAR γ of activation can promote fat
Certain and glucose transport and the expression using related gene, such as 4 (GluT- of insulin receptor and glucose transporter in tissue
4) etc.；On the other hand can inhibit the secretion of in-vivo tumour necrosin (TNF α) and leptin (leptin), mitigate this two
The insulin resistance that kind albumen generates, to play the effect for reducing blood glucose.It can be seen that the activation of PPAR γ and the absorption of glucose
There is very close connection between utilization, therefore, PPAR gamma modulators have become a kind of Remedies for diabetes.
Disclose a series of patent application of PPAR regulators at present, including WO2008143254,
WO2002080936、WO2011059053、CN201310221364.8、CN201310130440.4、CN200780101081.2
The mechanism of blood glucose regulation mediated Deng the mono- target spot of, PPAR has become the hot spot studied at present.
Summary of the invention
The object of the present invention is to provide a kind of prevention or the new machines for the treatment of diabetes, metabolic syndrome and its related disease
System.
New mechanism provided by the invention be adjust COX and/or GPR and/or PPAR multiple target point prevent or treat diabetes,
Application in metabolic syndrome and its related disease.
New mechanism provided by the invention is to adjust COX and/or GPR and/or PPAR multiple target point in protection islet beta cell function
In application.
New mechanism provided by the invention is that adjusting COX and/or GPR and/or PPAR multiple target point are preparing insulin secretion accelerating
Application in agent and insulin sensitizer.
New mechanism provided by the invention is the drug or medicine group by adjusting COX and/or GPR and/or PPAR multiple target point
It closes object and plays biological effect.
The COX includes COX-1 and COX-2 etc., but is not limited to citing range.
The GPR includes GPR40, GPR41, GPR43, GPR84, GPR119 and GPR120 etc., but is not limited to citing model
It encloses.
The PPAR includes PPAR α, PPAR δ and PPAR γ etc..
The drug includes COX regulator and/or GPR regulator and/or PPAR regulator.
The pharmaceutical composition, which is characterized in that the pharmaceutical composition includes that COX regulator and/or GPR are adjusted
Agent and/or PPAR regulator and one or more treatment diabetes medicaments.
The COX regulator includes COX-1 selective depressant, non-selective COX inhibitor, the suppression of COX-2 tendentiousness
Preparation, COX-2 highly selective inhibitor, are exemplified below: aspirin, benorylate, Indomethacin, sulindac, brufen, fluorine ratio
Ibuprofen, fenbufen, Fenbid, Ketoprofen, naproxen, Nabumetone, piroxicam, Meloxicam, celecoxib, Rofe former times
Cloth, watt moral former times cloth, SC 69124, according to appropriate former times cloth etc., but be not limited to citing range.
The GPR regulator include GPR40 regulator, GPR41 regulator, GPR43 regulator, GPR84 regulator,
GPR119 regulator and GPR120 regulator etc., but it is not limited to citing range.
The PPAR regulator include PPAR alfa agonists, PPAR delta agonists, PPAR gamma agonist, PPAR α/δ it is bis- by
Body agonist, PPAR α/γ amboceptor agonist, tri- receptor stimulating agent of PPAR δ/γ amboceptor agonist and PPAR α/δ/γ are lifted
Under such as: Rosiglitazone, Pioglitazone etc., but it is not limited to citing range.
The treatment diabetes medicament, including insulin, insulin analog, promotion islet β cell insulin
Drug, promote peripheral tissues increase glucose utilization drug, inhibit enteron aisle glucose absorption drug, insulin sensitivity enhancing
Agent, the drug for promoting glucose metabolism or the drug for inhibiting renal glucose reabsorption etc., but it is not limited to citing range.
The treatment diabetes medicament, preferred embodiment include insulin, insulin analog, glibenclamide, lattice column
Quinoline ketone, gliclazide, Glipizide, Glimepiride, Repaglinide, Nateglinide, melbine, insoral, Ciglitazone,
Rosiglitazone, Pioglitazone, Liraglutide, Exenatide, Li Sina peptide, albiglutide, acarbose, volt lattice wave sugar, meter Ge
Column alcohol, saxagliptin, Xi Gelieting, vildagliptin, Li Gelieting, Egelieting, song Ge Lieting, Dapagliflozin, canagliflozin,
Ai Gelie net, Ipragliflozin, Luseogliflozin and Tofogliflozin etc., but it is not limited to citing range.
The metabolic syndrome and its related disease is that the generation of the metabolisms such as protein, fat, carbohydrate is disorderly
Random pathological state, including obesity (Despr é s J P, Lemieux I, Alm é ras N. Abdominal obesity
and the metabolic syndrome [M] Overweight and the Metabolic Syndrome.
Springer US, 2006:137-152), hyperglycemia (Grundy S M, Cleeman J I, Daniels S R, et
al. Diagnosis and management of the metabolic syndrome [J]. Circulation,
2005,112 (17): 2735-2752), dyslipidemia (Charlton M. Obesity, hyperlipidemia, and
Metabolic syndrome [J] Liver Transplantation, 2009,15 (S2)), high blood it is glutinous (Irace C,
Scavelli F, Carallo C, et al. Plasma and blood viscosity in metabolic
syndrome [J]. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19(7):
476-480), high lithemia (Yoo T W, Sung K C, Shin H S, et al. Relationship between
serum uric acid concentration and insulin resistance and metabolic syndrome
[J] Circulation Journal, 2005,69 (8): 928-933), high-fat liver (Marchesini G,
Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and
The metabolic syndrome [J] Hepatology, 2003,37 (4): 917-923) and hyperinsulinemia
(Han T S, Williams K, Sattar N, et al. Analysis of obesity and
hyperinsulinemia in the development of metabolic syndrome: San Antonio Heart
Study [J] Obesity, 2002,10 (9): 923-931) etc., but be not limited to citing range (Grundy S M,
Brewer H B, Cleeman J I, et al. Definition of metabolic syndrome [J].
Circulation, 2004,109 (3): 433-438).
The drug or pharmaceutical composition of the treatment diabetes, metabolic syndrome and its related disease can pass through oral, note
It penetrates, spray, collunarium, eye drip, infiltration, absorption, the method that physically or chemically mediates import body such as muscle, skin and flesh, subcutaneous, quiet
Arteries and veins, mucosal tissue, or body is imported after other material mixings or package, but be not limited to citing range.
When needs, it can also be added in said medicine or pharmaceutical composition one or more pharmaceutically acceptable
Carrier.The carrier includes diluent, excipient, filler, adhesive, wetting agent, the disintegrating agent, absorption of pharmaceutical field routine
Promotor, surfactant, absorption carrier, lubricant etc., but it is not limited to citing range.
The prevention or treatment diabetes, metabolism prepared using the drug or pharmaceutical composition that act on the mechanism as active constituent
Injection, tablet, pulvis, granule, capsule, oral solution, paste, frost can be made in the drug of syndrome and its related disease
The diversified forms such as agent, but it is not limited to citing range.The drug of above-mentioned various dosage forms can be according to the conventional method of pharmaceutical field
Preparation.
Detailed description of the invention
" pharmaceutical composition " is indicated containing one or more COX regulators and/or GPR regulator and/or PPAR regulator and its
The mixture of his chemical constituent, for example pharmaceutical carrier of other chemical constituents and excipient.The purpose of pharmaceutical composition is to promote
Absorption into organism to active constituent plays bioactivity conducive to active constituent in vivo.
Specific embodiment
The present invention is explained in following biology testing example description.
The experimental method of actual conditions usually routinely condition or is built according to commodity manufacturer in test case of the present invention
The condition of view.The reagent in specific source is not specified, for the common agents of market purchase.
Test case 1: the internal hypoglycemic activity of compound can be surveyed by using measurement system as described below in the present invention
It is fixed.
Normal mouse oral glucose tolerance drops experiments have shown that brufen and TAK-875 drug combination than TAK-875 independent medication
Hypoglycemic effect is remarkably reinforced, hence it is evident that reduces the dosage of TAK-875
Normal mouse oral glucose tolerance tests (OGTT): 10 week old cleaning grade ICR mouse (Qinglongshan animal experimental center, Jiangsu
Nanjing), 20~24 g of weight, male is randomly divided into 4 groups, group 1: blank control group (blank solvent: 0.5% carboxymethyl cellulose
Element), group 2: positive drug control group (TAK-875:20 mg/kg), group 3: brufen (25 mg/kg) combines TAK-875(10 mg/
Kg), organize 4: brufen (50 mg/kg), every group 8, mouse is deprived of food but not water 12 hours before testing, and the equal oral administration gavage of each group is given
Medicine, docking take blood, measure blood glucose value.Then blank solvent, TAK-875, brufen joint TAK- are given in stomach-filling to 4 groups of mouse respectively
Measurement blood glucose value is denoted as 0 min after 875 and brufen, 30 min, and stomach-filling immediately later is given glucose (2 g/kg), and in
15,30,60,120 min measure blood glucose value.It the results are shown in Table 1.
Table 1: influence (± SD, n=8) of the compound to normal mouse oral glucose tolerance
Test case 2: the internal hypoglycemic activity of compound can be by using measurement system measurement as described below in the present invention.
Diabetes C57BL/6 mouse oral sugar tolerance can be controlled effectively experiments have shown that brufen and TAK-875 drug combination
The blood glucose of diabetes C57BL/6 mouse processed, reduces the dosage of TAK-875
Diabetes C57BL/6 mouse oral sugar tolerance tests (OGTT): diabetes C57BL/6 mouse, and 30~36 g of weight is male
Property, 4 groups are randomly divided into, group 1: blank control group (blank solvent: 0.5% carboxymethyl cellulose), group 2: positive drug control group
(TAK-875:20 mg/kg), group 3: brufen (25 mg/kg) combines TAK-875(10 mg/kg), group 4: brufen (50
Mg/kg), every group 8, mouse is deprived of food but not water 12 hours before testing, and the equal oral administration gavage administration of each group, docking takes blood, measures blood
Sugar value.Then blank solvent, TAK-875, brufen joint TAK-875 and brufen, 30 min are given in stomach-filling to 4 groups of mouse respectively
Measurement blood glucose value is denoted as 0 min afterwards, and glucose (1.5 g/kg) is given in stomach-filling immediately later, and in 15,30,60,120 min
Measure blood glucose value.It the results are shown in Table 2.
Table 2: influence (± SD, n=8) of the compound to diabetes C57BL/6 mouse oral sugar tolerance
Test case 3: the internal hypoglycemic activity of compound can be by using measurement system measurement as described below in the present invention.
Normal mouse oral glucose tolerance is experiments have shown that brufen and Pioglitazone drug combination, than Pioglitazone independent medication
Blood sugar decreasing effect is remarkably reinforced, hence it is evident that reduces the dosage of Pioglitazone
Normal mouse oral glucose tolerance tests (OGTT): 10 week old cleaning grade ICR mouse (Qinglongshan animal experimental center, Jiangsu
Nanjing), 20~24 g of weight, male is randomly divided into 4 groups, group 1: blank control group (blank solvent: 0.5% carboxymethyl cellulose
Element), group 2: positive drug control group (Pioglitazone: 3.0 mg/kg), group 3: brufen (25 mg/kg) combines Pioglitazone (1.5
Mg/kg), organize 4: brufen (50 mg/kg), every group 8, mouse is deprived of food but not water 12 hours before testing, the equal oral administration gavage of each group
Administration, docking take blood, measure blood glucose value.Then blank solvent, Pioglitazone, brufen joint are given in stomach-filling to 4 groups of mouse respectively
Pioglitazone and brufen, measurement blood glucose value is denoted as 0 min after 30 min, and glucose (2 g/kg) is given in stomach-filling immediately later,
And blood glucose value is measured in 15,30,60,120 min.It the results are shown in Table 3.
Table 3: influence (± SD, n=8) of the compound to normal mouse oral glucose tolerance
Test case 4: the internal hypoglycemic activity of compound can be by using measurement system measurement as described below in the present invention.
Diabetes C57BL/6 mouse oral sugar tolerance, can be effective experiments have shown that brufen and Pioglitazone drug combination
The blood glucose for controlling diabetes C57BL/6 mouse, reduces the dosage of Pioglitazone
Diabetes C57BL/6 mouse oral sugar tolerance tests (OGTT): diabetes C57BL/6 mouse, and 30~36 g of weight is male
Property, 4 groups are randomly divided into, group 1: blank control group (blank solvent: 0.5% carboxymethyl cellulose), group 2: positive drug control group
(Pioglitazone: 3.0 mg/kg), group 3: brufen (25 mg/kg) combines Pioglitazone (1.5 mg/kg), group 4: brufen
(50 mg/kg), every group 8, mouse is deprived of food but not water 12 hours before testing, and the equal oral administration gavage administration of each group, docking takes blood, surveys
Determine blood glucose value.Then blank solvent, Pioglitazone, brufen joint Pioglitazone and brufen are given in stomach-filling to 4 groups of mouse respectively,
Blood glucose value is measured after 30 min is denoted as 0 min, stomach-filling immediately later is given glucose (1.5 g/kg), and in 15,30,60,
120 min measure blood glucose value.It the results are shown in Table 4.
Table 4: influence (± SD, n=8) of the compound to diabetes C57BL/6 mouse oral sugar tolerance
Test case 5: the internal hypoglycemic activity of compound can be by using measurement system measurement as described below in the present invention.
Normal mouse oral glucose tolerance can effectively control diabetes experiments have shown that brufen and melbine drug combination
The blood glucose of C57BL/6 mouse reduces the dosage of melbine
Normal mouse oral glucose tolerance tests (OGTT): 10 week old cleaning grade ICR mouse (Qinglongshan animal experimental center, Jiangsu
Nanjing), 20~24 g of weight, male is randomly divided into 4 groups, group 1: blank control group (blank solvent: 0.5% carboxymethyl cellulose
Element), group 2: positive drug control group (100 mg/kg of melbine), group 3: brufen (25 mg/kg) combines melbine (50
Mg/kg), organize 4: brufen (50 mg/kg), every group 8, mouse is deprived of food but not water 12 hours before testing, the equal oral administration gavage of each group
Administration, docking take blood, measure blood glucose value.Then compound is given in stomach-filling to 4 groups of mouse respectively, and measurement blood glucose value is denoted as after 30 min
0 min, later stomach-filling immediately are given glucose (2 g/kg), and measure blood glucose value in 15,30,60,120 min.It the results are shown in Table
5。
Table 5: influence (± SD, n=8) of the compound to normal mouse oral glucose tolerance
Test case 6: the internal hypoglycemic activity of compound can be by using measurement system measurement as described below in the present invention.
Diabetes C57BL/6 mouse oral sugar tolerance, can be effective experiments have shown that brufen and melbine drug combination
The blood glucose for controlling diabetes C57BL/6 mouse, reduces the dosage of melbine
Diabetes C57BL/6 mouse oral sugar tolerance tests (OGTT): diabetes C57BL/6 mouse, and 30~36 g of weight is male
Property, 4 groups are randomly divided into, group 1: blank control group (blank solvent: 0.5% carboxymethyl cellulose), group 2: positive drug control group
(100 mg/kg of first biguanides), group 3: brufen (25 mg/kg) combines melbine (50 mg/kg), group 4: brufen (50
Mg/kg), every group 8, mouse is deprived of food but not water 12 hours before testing, and the equal oral administration gavage administration of each group, docking takes blood, measures blood
Sugar value.Then blank solvent, melbine, brufen joint melbine and brufen are given in stomach-filling to 4 groups of mouse respectively, and 30
Blood glucose value is measured after min and is denoted as 0 min, and glucose (1.5 g/kg) is given in stomach-filling immediately later, and in 15,30,60,120
Min measures blood glucose value.It the results are shown in Table 6.
Table 6: influence (± SD, n=8) of the compound to diabetes C57BL/6 mouse oral sugar tolerance
Claims (10)
1. the mechanism of blood glucose regulation based on COX and/or GPR and/or PPAR multiple target point.
2. drug or pharmaceutical composition based on the preparation of the mechanism of blood glucose regulation of COX and/or GPR and/or PPAR multiple target point are pre-
Application in anti-or treatment diabetes, metabolic syndrome and its related disease.
3. drug or pharmaceutical composition based on COX and/or GPR and/or PPAR multiple target point are in the medicine for preparing insulin secretion accelerating
Object and/or prepare insulin sensitivity enhancing drug and/or preparation protection beta Cell of islet drug in application.
4. COX described in claim 1-3 includes COX-1 and COX-2 etc., but is not limited to citing range；The GPR includes
GPR40, GPR41, GPR43, GPR84, GPR119 and GPR120 etc., but it is not limited to citing range；The PPAR includes PPAR
α, PPAR δ and PPAR γ etc..
5. drug described in claim 2-3 includes COX regulator and/or GPR regulator and/or PPAR regulator；Described
Pharmaceutical composition includes COX regulator and/or GPR regulator and/or PPAR regulator and one or more treatment Rezulins
Object.
6. COX regulator described in claim 5 includes COX-1 selective depressant, non-selective COX inhibitor, COX-2
Tendentiousness inhibitor or COX-2 highly selective inhibitor etc., are exemplified below: aspirin, benorylate, Indomethacin, sulindac,
Brufen, fenbufen, Fenbid, Ketoprofen, naproxen, Nabumetone, piroxicam, Meloxicam, is filled in and carrys out former times Flurbiprofen
Cloth, rofecoxib, watt moral former times cloth, SC 69124, according to appropriate former times cloth etc., but be not limited to citing range；The GPR regulator includes
GPR40 regulator, GPR41 regulator, GPR43 regulator, GPR84 regulator, GPR119 regulator or GPR120 regulator etc.,
But it is not limited to citing range；The PPAR regulator include PPAR alfa agonists, PPAR delta agonists, PPAR gamma agonist,
PPAR α/δ amboceptor agonist, PPAR α/γ amboceptor agonist, PPAR δ/γ amboceptor agonist and PPAR α/δ/γ tri- by
Body agonist, is exemplified below: Rosiglitazone, Pioglitazone etc., but is not limited to citing range.
7. treatment diabetes medicament described in claim 5, including insulin, insulin analog, promotion islet β cell
The drug of insulin promotes peripheral tissues to increase the drug of glucose utilization, inhibit drug, the insulin of enteron aisle glucose absorption
Sensitizer, the drug for promoting glucose metabolism or the drug for inhibiting renal glucose reabsorption etc., preferred embodiment includes pancreas
Island element, insulin analog, glibenclamide, gliquidone, gliclazide, Glipizide, Glimepiride, Repaglinide, that lattice
Column how, melbine, insoral, Ciglitazone, Rosiglitazone, Pioglitazone, Liraglutide, Exenatide, Li Sina peptide,
Albiglutide, acarbose, volt lattice wave sugar, Miglitol, saxagliptin, Xi Gelieting, vildagliptin, Li Gelieting, A Ge
Arrange spit of fland, song Ge Lieting, Dapagliflozin, canagliflozin, Ai Gelie only, Ipragliflozin, Luseogliflozin and
Tofogliflozin etc., but it is not limited to citing range.
8. drug described in claim 2-2 or pharmaceutical composition can pass through oral, injection, injection, collunarium, eye drip, infiltration, suction
It receives, the method that physically or chemically mediates imports body such as muscle, skin and flesh, subcutaneous, vein, mucosal tissue or by other substances
Body etc. is imported after mixing or package, but is not limited to citing range.
9. one or more pharmaceutically acceptable loads can also be added in drug described in claim 2-3 or pharmaceutical composition
Body etc., the carrier include diluent, excipient, filler, adhesive, wetting agent, the disintegrating agent, absorption of pharmaceutical field routine
Promotor, surfactant, absorption carrier, lubricant etc., but it is not limited to citing range.
10. drug described in claim 2-3 or pharmaceutical composition, the drug or pharmaceutical composition can be made into injection, tablet,
The diversified forms such as pulvis, granule, capsule, oral solution, paste, creme, but it is not limited to citing range.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710781391.9A CN109420175A (en) | 2017-09-01 | 2017-09-01 | Mechanism of blood glucose regulation based on COX |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710781391.9A CN109420175A (en) | 2017-09-01 | 2017-09-01 | Mechanism of blood glucose regulation based on COX |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109420175A true CN109420175A (en) | 2019-03-05 |
Family
ID=65513053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710781391.9A Pending CN109420175A (en) | 2017-09-01 | 2017-09-01 | Mechanism of blood glucose regulation based on COX |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109420175A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220127588A (en) * | 2021-03-11 | 2022-09-20 | 중앙대학교 산학협력단 | Composition for Prevention or treatment of Diabetes Comprising Valdecoxib |
| CN115300627A (en) * | 2021-05-08 | 2022-11-08 | 中南大学湘雅医院 | Application of sodium-glucose cotransporter 2 inhibitor, pharmaceutical composition and application thereof |
| CN115572223A (en) * | 2022-10-17 | 2023-01-06 | 聊城大学 | Phenylpropionic acid derivative and application thereof |
| CN115698269A (en) * | 2020-05-29 | 2023-02-03 | 株式会社Numt | Adipocytes highly expressing FFAR4 and their use |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216522A (en) * | 1996-02-19 | 1999-05-12 | 日本烟草产业株式会社 | Therapeutic agent for diabetes |
| CN1642544A (en) * | 2002-01-14 | 2005-07-20 | 法马西亚公司 | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| CN1646480A (en) * | 2002-04-15 | 2005-07-27 | 财团法人牧岩生命工学研究所 | Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| CN101106991A (en) * | 2005-01-28 | 2008-01-16 | 默克公司 | Antidiabetic bicyclic compounds |
| CN101534822A (en) * | 2006-09-15 | 2009-09-16 | 先灵公司 | Treating pain, diabetes, and disorders of lipid metabolism |
| CN102186825A (en) * | 2008-10-21 | 2011-09-14 | 麦它波莱克斯股份有限公司 | Aryl gpr120 receptor agonists and uses thereof |
| WO2011140078A1 (en) * | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| CN105418563A (en) * | 2015-12-28 | 2016-03-23 | 山东大学 | TAK-875 analog, and preparation method and application thereof |
-
2017
- 2017-09-01 CN CN201710781391.9A patent/CN109420175A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216522A (en) * | 1996-02-19 | 1999-05-12 | 日本烟草产业株式会社 | Therapeutic agent for diabetes |
| CN1642544A (en) * | 2002-01-14 | 2005-07-20 | 法马西亚公司 | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
| CN1646480A (en) * | 2002-04-15 | 2005-07-27 | 财团法人牧岩生命工学研究所 | Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| CN101106991A (en) * | 2005-01-28 | 2008-01-16 | 默克公司 | Antidiabetic bicyclic compounds |
| CN101534822A (en) * | 2006-09-15 | 2009-09-16 | 先灵公司 | Treating pain, diabetes, and disorders of lipid metabolism |
| CN102186825A (en) * | 2008-10-21 | 2011-09-14 | 麦它波莱克斯股份有限公司 | Aryl gpr120 receptor agonists and uses thereof |
| WO2011140078A1 (en) * | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| CN105418563A (en) * | 2015-12-28 | 2016-03-23 | 山东大学 | TAK-875 analog, and preparation method and application thereof |
Non-Patent Citations (4)
| Title |
|---|
| TAHEREH TABATABAIE ET AL: "COX-2 Inhibition Prevents Insulin-Dependent Diabetes in Low-Dose Streptozotocin-Treated Mice", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
| ZHENG LI ETAL: "Design, Synthesis and Structure−Activity Relationship Studies of New Thiazole-Based Free Fatty Acid Receptor 1 Agonists for the Treatment of Type 2 Diabetes", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
| 姚燕琴等: "阿司匹林对糖尿病模型大鼠血糖的影响", 《中国药师》 * |
| 项金华: "血管紧张素转化酶抑制剂联合环氧化酶2抑制剂治疗糖尿病肾病的临床观察", 《中国现代医学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115698269A (en) * | 2020-05-29 | 2023-02-03 | 株式会社Numt | Adipocytes highly expressing FFAR4 and their use |
| KR20220127588A (en) * | 2021-03-11 | 2022-09-20 | 중앙대학교 산학협력단 | Composition for Prevention or treatment of Diabetes Comprising Valdecoxib |
| KR102497760B1 (en) | 2021-03-11 | 2023-02-08 | 중앙대학교 산학협력단 | Composition for Prevention or treatment of Diabetes Comprising Valdecoxib |
| CN115300627A (en) * | 2021-05-08 | 2022-11-08 | 中南大学湘雅医院 | Application of sodium-glucose cotransporter 2 inhibitor, pharmaceutical composition and application thereof |
| CN115300627B (en) * | 2021-05-08 | 2024-01-26 | 中南大学湘雅医院 | Application of sodium-glucose cotransporter 2 inhibitor, pharmaceutical composition and application thereof |
| CN115572223A (en) * | 2022-10-17 | 2023-01-06 | 聊城大学 | Phenylpropionic acid derivative and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chadwick et al. | Anti-diabetic effects of Sutherlandia frutescens in Wistar rats fed a diabetogenic diet | |
| CN109420175A (en) | Mechanism of blood glucose regulation based on COX | |
| Gupta et al. | Key milestones in the diabetes research: A comprehensive update | |
| CN109640993A (en) | Comprising amodiaquine and antidiabetic medicine as effective component for preventing or treating the pharmaceutical compositions of diabetes | |
| Prasathkumar et al. | Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: an insight on molecular approaches | |
| CN117323323A (en) | Activating effect of Qinan ingredients on AMPK | |
| US11920157B2 (en) | Applications of butylidenephthalide | |
| JP2018516841A (en) | Anti-diabetic effect of dipenoside 75 | |
| CN103735550B (en) | A kind of pharmaceutical composition and application thereof for the treatment of chronic kidney disease myocardial damage | |
| KR20160011329A (en) | A Pharmaceutical composition comprising extract of Coptidis Rhizoma for enhancing the therapy of diabetes Mellitus and obesity | |
| CN108261412A (en) | Purposes of the leonurine in insulin sensitizer is prepared | |
| Roy | Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report | |
| CN103181945B (en) | The purposes of Semen Luffae | |
| CN109419791A (en) | New application of the fenbufen as diabetes related target regulator | |
| Behl et al. | Targeting Angiogenesis, Inflammation and Oxidative Stress in Chronic Diseases: Angiogenesis, Inflammation and Oxidative Stress in Chronic Diseases | |
| CN101347511B (en) | Medicament composition with function for reducing blood sugar | |
| CN106466325B (en) | A kind of medicine, composition and preparation for preventing or treating diabetes | |
| CN114306601A (en) | Method for effectively intervening diabetes by using L-type amino acid transporter inhibitor or antagonist | |
| Haque et al. | Pharmacological management of diabetes | |
| WO2018219033A1 (en) | Multi-drug combined rehabilitation electuary for type 2 diabetes and use thereof | |
| KR100732614B1 (en) | Pharmaceutical composition for the prevention or treatment of obesity or diabetic disease comprising blowfish extract | |
| CN103948591B (en) | A kind of slimming agents | |
| CN109481424A (en) | Isoliquiritigenin, pharmaceutical composition and its application in treatment diabetic nephropathy | |
| CN116139160B (en) | Application of verbena glycoside in treating diabetes and/or diabetic complications | |
| Mannucci et al. | Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190305 |
|
| WD01 | Invention patent application deemed withdrawn after publication |